LOGIN  |  REGISTER
Astria Therapeutics
Terns Pharmaceuticals

NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th

March 19, 2025 | Last Trade: US$1.59 0.04 -2.52
  • Management will host a conference call at 4:30 p.m. ET on the same day

LANGHORNE, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2024, after the market closes on March 24, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day.

Fourth Quarter and Full Year 2024 Financial Results Conference Call
Date: March 24, 2025
Time: 4:30 p.m. ET
Live Call: 1-800-245-3047 (U.S. Toll Free) or 1-203-518-9765 (International)
Webcast: Events and Presentations

For interested individuals unable to join the conference call, a replay will be available through April 3, 2025 by dialing 1-844-512-2921(U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11158402. An archive of the webcast will also be available for 90 days.

About NEXGEL, INC.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page